ENSEM develops small molecule precision medicines for oncology using its Kinetic Ensemble® platform, which combines AI deep learning with experimental techniques to identify cryptic binding pockets in drug targets. This approach enables the discovery of therapeutic interventions for traditionally undruggable targets, addressing the challenge of drug resistance and enhancing treatment options for cancer patients.
Funding
$77M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer drug targets are considered "undruggable" due to a lack of accessible binding sites, leading to limited treatment options and drug resistance. Traditional drug discovery methods often fail to identify cryptic binding pockets that could be exploited for therapeutic intervention.
Solution
ENSEM utilizes its Kinetic Ensemble® platform to discover small molecule precision medicines for oncology by targeting cryptic binding pockets in traditionally undruggable proteins. The platform combines AI deep learning with experimental techniques to map protein kinetic states at ultra-high resolution, revealing hidden pockets that are not apparent in static protein structures. This approach enables the design of novel therapeutic interventions that can overcome drug resistance and expand the range of treatable cancer targets. By focusing on these cryptic pockets, ENSEM aims to create new opportunities for therapeutic intervention and address previously intractable oncology targets.
Target Audience
The primary target audience includes oncology researchers and pharmaceutical companies focused on developing novel treatments for cancers with limited therapeutic options or drug resistance.
Features
- Kinetic Ensemble® platform integrating AI deep learning and experimental techniques
- Identification of cryptic binding pockets in traditionally undruggable targets
- Structure-based drug design targeting comprehensive kinetic states at ultra-high resolution
- Focus on high-value and difficult-to-drug oncology targets
- Pipeline of small molecule precision medicines